We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
+19.21%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$1.9M
Cap. Flow
-$30.9M
Cap. Flow %
-9.55%
Top 10 Hldgs %
61.81%
Holding
89
New
17
Increased
17
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
PCOR icon
Procore
PCOR
+$6.97M
2
ORIC icon
Oric Pharmaceuticals
ORIC
+$5.93M
3
MPLT
MapLight Therapeutics
MPLT
+$5.48M
4
PAYO icon
Payoneer
PAYO
+$4.81M
5
LENZ
LENZ Therapeutics
LENZ
+$4.37M

Top Sells

Rank Stock Value
1
EVCM icon
EverCommerce
EVCM
+$18.3M
2
ROIV icon
Roivant Sciences
ROIV
+$14.3M
3
NCDL icon
Nuveen Churchill Direct Lending
NCDL
+$13.5M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.9M
5
IRON icon
Disc Medicine
IRON
+$6.76M

Sector Composition

Rank Sector Weight
1 Healthcare 63.81%
2 Financials 18.18%
3 Technology 8.81%
4 Consumer Discretionary 7.9%
5 Energy 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENGN icon
1
enGene Therapeutics
ENGN
$120M
$30.3M 9.37%
3,360,937
+82,831
+3% +$664K
NCDL icon
2
Nuveen Churchill Direct Lending
NCDL
$609M
$28.6M 8.82%
2,143,626
-947,927
-31% -$13.5M
OBDC icon
3
Blue Owl Capital
OBDC
$5.35B
$26.1M 8.06%
2,045,070
– –
LRMR icon
4
Larimar Therapeutics
LRMR
$377M
$26M 8.02%
6,823,690
+970,650
+17% +$3.78M
CGEM icon
5
Cullinan Oncology
CGEM
$1.06B
$24.3M 7.51%
2,350,972
-160,000
-6% -$1.44M
CMPX icon
6
Compass Therapeutics
CMPX
$349M
$18.6M 5.74%
3,466,525
+875,000
+34% +$4.04M
HLLY icon
7
Holley
HLLY
$335M
$17.1M 5.29%
4,146,636
-715,725
-15% -$2.58M
CNTX icon
8
Context Therapeutics
CNTX
$56.7M
$10.9M 3.37%
7,432,906
+25,000
+0.3% +$29.2K
CNDT icon
9
Conduent
CNDT
$253M
$9.26M 2.86%
4,822,422
+365,574
+8% +$801K
RPTX
10
DELISTED
Repare Therapeutics
RPTX
$8.95M 2.76%
3,443,659
– –
CVEO icon
11
Civeo
CVEO
$356M
$8.47M 2.62%
370,530
+53,119
+17% +$1.18M
SGMT icon
12
Sagimet Biosciences
SGMT
$435M
$7.36M 2.27%
1,243,877
-84,474
-6% -$607K
EYPT icon
13
EyePoint Inc
EYPT
$999M
$7.17M 2.21%
392,594
+25,000
+7% +$354K
PCOR icon
14
Procore
PCOR
$7.57B
$6.86M 2.12%
+94,264
New +$6.97M
DELL icon
15
Dell
DELL
$239B
$6.78M 2.09%
53,848
+1,514
+3% +$213K
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
$5.81M 1.79%
360,000
+235,000
+188% +$3.11M
MPLT
17
MapLight Therapeutics
MPLT
$681M
$5.74M 1.77%
+327,058
New +$5.48M
ROIV icon
18
Roivant Sciences
ROIV
$23.6B
$5.71M 1.76%
263,249
-725,000
-73% -$14.3M
IMA
19
ImageneBio Inc
IMA
$63.4M
$5.68M 1.75%
823,785
+282,861
+52% +$2.1M
IMMX icon
20
Immix Biopharma
IMMX
$582M
$5.16M 1.59%
+986,240
New +$4.06M
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$2.46B
$4.89M 1.51%
212,638
-209,800
-50% -$6.9M
IMRX icon
22
Immuneering
IMRX
$262M
$4.38M 1.35%
665,000
+115,000
+21% +$738K
PVLA
23
Palvella Therapeutics
PVLA
$2.05B
$4.21M 1.3%
40,259
-55,000
-58% -$4.69M
ORIC icon
24
Oric Pharmaceuticals
ORIC
$1.17B
$4.21M 1.3%
+515,000
New +$5.93M
PAYO icon
25
Payoneer
PAYO
$2.41B
$3.98M 1.23%
+832,810
New +$4.81M
1
2 3 4

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $372M AUM 50.62% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return

Blue Owl Capital Holdings's Q4 2025 Portfolio in Review

As of Q4 2025, Blue Owl Capital Holdings held 89 positions worth $324M, up 0.59% from $322M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Blue Owl Capital Holdings withdrew a net $30.9M in Q4 2025, closing 9 positions and reducing 13 holdings. Its most notable exit was EverCommerce, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 57% a quarter earlier, followed by Financials and Technology.

Against the trend, Blue Owl Capital Holdings opened a new position in Procore worth $6.86M.

  • Blue Owl Capital Holdings's largest Q4 2025 buy was Procore: 94,264 shares worth $6.86M.
  • Blue Owl Capital Holdings added most to Compass Therapeutics in Q4 2025, an estimated $4.04M increase.
  • Blue Owl Capital Holdings's biggest Q4 2025 reduction was Roivant Sciences, cutting an estimated $14.3M.
  • Blue Owl Capital Holdings fully exited EverCommerce in Q4 2025, selling an estimated $18.3M.
  • Blue Owl Capital Holdings's ten largest holdings make up 62% of its $324M portfolio in Q4 2025.
  • Blue Owl Capital Holdings opened 17 new positions and closed 9 in Q4 2025.
  • Blue Owl Capital Holdings's portfolio value rose 0.59% quarter-over-quarter to $324M.

Based on Blue Owl Capital Holdings's 13F filing for Q4 2025, filed 9 Feb 2026.